Cargando…

Nanophytomedicines as Therapeutic Agents for Parkinson’s Disease

[Image: see text] Phytochemicals are promising therapeutics for various neurodegenerative disorders, including Parkinson’s disease (PD). However, their efficacy, pharmacokinetic properties, and penetration across the blood–brain barrier can be improved using delivery systems such as nanoparticles. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burns, Jessica, Buck, Amy Claire, D’ Souza, Sarah, Dube, Admire, Bardien, Soraya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652730/ https://www.ncbi.nlm.nih.gov/pubmed/38024675 http://dx.doi.org/10.1021/acsomega.3c04862

Ejemplares similares

Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases
por: Hesari, Mahvash, et al.
Publicado: (2021)

Nanophytomedicines for the Prevention of Metabolic Syndrome: A Pharmacological and Biopharmaceutical Review
por: Nouri, Zeinab, et al.
Publicado: (2020)

In vitro–in vivo assessments of apocynin-hybrid nanoparticle-based gel as an effective nanophytomedicine for treatment of rheumatoid arthritis
por: Aman, Reham Mokhtar, et al.
Publicado: (2023)

Current Status of Next-Generation Sequencing Approaches for Candidate Gene Discovery in Familial Parkinson´s Disease
por: Pillay, Nikita Simone, et al.
Publicado: (2022)

Parkinson's Disease Research on the African Continent: Obstacles and Opportunities
por: Dekker, Marieke C. J., et al.
Publicado: (2020)

Editorial: Celebrating the Diversity of Genetic Research to Dissect the Pathogenesis of Parkinson's Disease
por: Farrer, Matthew J., et al.
Publicado: (2021)

Association Between a Variable Number Tandem Repeat Polymorphism Within the DAT1 Gene and the Mesolimbic Pathway in Parkinson's Disease
por: du Plessis, Stefan, et al.
Publicado: (2020)

Prioritization of candidate genes for a South African family with Parkinson’s disease using in-silico tools
por: Sebate, Boiketlo, et al.
Publicado: (2021)

Curcumin pre-treatment may protect against mitochondrial damage in LRRK2-mutant Parkinson's disease and healthy control fibroblasts
por: Abrahams, Shameemah, et al.
Publicado: (2021)

Proteomics analysis of the p.G849D variant in neurexin 2 alpha may reveal insight into Parkinson’s disease pathobiology
por: Cuttler, Katelyn, et al.
Publicado: (2022)

Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
por: Moors, Tim E., et al.
Publicado: (2017)

Mitochondrial DNA variation in Parkinson’s disease: Analysis of “out-of-place” population variants as a risk factor
por: Müller-Nedebock, Amica C., et al.
Publicado: (2022)

Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease
por: Grimmig, Bethany, et al.
Publicado: (2016)

BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
por: Palasz, Ewelina, et al.
Publicado: (2020)

Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
por: Nwabufo, Chukwunonso K., et al.
Publicado: (2022)

Altered Mitochondrial Respiration and Other Features of Mitochondrial Function in Parkin-Mutant Fibroblasts from Parkinson's Disease Patients
por: Haylett, William, et al.
Publicado: (2016)

RNA-seq analysis of gene expression profiles in posttraumatic stress disorder, Parkinson’s disease and schizophrenia identifies roles for common and distinct biological pathways
por: Hemmings, Sian M. J., et al.
Publicado: (2022)

Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound?
por: Stefani, Alessandro, et al.
Publicado: (2022)

Recent Advances in the Development of Antimicrobial and Antifouling Biocompatible Materials for Dental Applications
por: Ramburrun, Poornima, et al.
Publicado: (2021)

Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles
por: Khoza, Leon J., et al.
Publicado: (2022)

Cathelicidins and defensins antimicrobial host defense peptides in the treatment of TB and HIV: Pharmacogenomic and nanomedicine approaches towards improved therapeutic outcomes
por: Dlozi, Prince N., et al.
Publicado: (2022)

Emerging evidence implicating a role for neurexins in neurodegenerative and neuropsychiatric disorders
por: Cuttler, Katelyn, et al.
Publicado: (2021)

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease
por: Miller, Sean J., et al.
Publicado: (2023)

Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences
por: de Andrade Teles, Roxana Braga, et al.
Publicado: (2018)

Identifying Therapeutic Agents for Amelioration of Mitochondrial Clearance Disorder in Neurons of Familial Parkinson Disease
por: Yamaguchi, Akihiro, et al.
Publicado: (2020)

Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches
por: Cruz-Vicente, Pedro, et al.
Publicado: (2021)

The Role of Pathogens and Anti-Infective Agents in Parkinson’s Disease, from Etiology to Therapeutic Implications
por: Shen, Si, et al.
Publicado: (2022)

A Perspective on Nanotechnology and COVID-19 Vaccine Research and Production in South Africa
por: Dube, Admire, et al.
Publicado: (2021)

Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease
por: Müller-Nedebock, Amica C., et al.
Publicado: (2023)

Newer Dopaminergic Agents Cause Minimal Endocrine Effects in Idiopathic Parkinson’s Disease
por: Daniel, Jacob S, et al.
Publicado: (2014)

The Promise of Neuroprotective Agents in Parkinson’s Disease
por: Seidl, Stacey E., et al.
Publicado: (2011)

Could exercise hormone irisin be a therapeutic agent against Parkinson’s and other neurodegenerative diseases?
por: Avgerinos, Konstantinos I., et al.
Publicado: (2023)

Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review
por: Koshatwar, Mahima, et al.
Publicado: (2023)

The domestication of the African Union model law on medical products regulation: Perceived benefits, enabling factors, and challenges
por: Ncube, Bakani Mark, et al.
Publicado: (2023)

Situation analysis on the regulation of nanomedicines in Southern Africa
por: Mudyiwenyama, Linda G., et al.
Publicado: (2023)

The Macrophage Response to Mycobacterium tuberculosis and Opportunities for Autophagy Inducing Nanomedicines for Tuberculosis Therapy
por: Maphasa, Retsepile E., et al.
Publicado: (2021)

Establishment of the African Medicines Agency: progress, challenges and regulatory readiness
por: Ncube, Bakani Mark, et al.
Publicado: (2021)

Collaborative reliance in medicine safety and quality regulation: Investigation of experiences in handling N-nitrosamine impurities among ZaZiBoNa participating countries
por: Shabangu, Patience P., et al.
Publicado: (2022)

Erratum: The promise of neuroprotective agents in Parkinson's disease
por: Seidl, Stacey E., et al.
Publicado: (2013)

Recent Progress of Imaging Agents for Parkinson's Disease
por: Wu, Xiaoai, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ioc5agmtq6702r7q61n3k8q62m